Gary Hiller
Phytecs is a biotechnology company developing therapies that target the body’s endocannabinoid system (ECS). Phytecs’ lead semi-synthetic drug candidate is a propriety, fluorinated CBD (F-CBD) compound. Preclinical research demonstrates that F-CBD mimics traditional CBD pharmacology with significantly lower dose requirements. Phytecs’ development pipeline also includes proprietary raw materials and formulations that leverage the synergistic effects of natural compound to produce medicines that are more effective, and safer, than those commonly found in botanicals or isolated natural compounds. Phytecs’ robust patent portfolio spans three continents and is the direct result of its unwavering commitment to research and innovation.